Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Sponsor
Huazhong University of Science and Technology
Study ID
NCT03598348
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a multicenter, randomized, controlled trial to evaluate the efficacy and safety of Maintenance Treatment with Capecitabine plus Apatinib, Apatinib and Observation after First-line XELOX/SOX chemotherapy for Patients with Advanced Gastric Cancer

Key Dates

Start date
Jan 16, 2018
Status verified
Jul 2018
Primary completion
Jan 16, 2020
Completion
Oct 16, 2020

Study Design

Enrollment
288 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Maintenance Treatment Group A
    Maintenance Treatment with Capecitabine plus Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
  • No Intervention: Observation Group
    Observation after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer
  • Experimental: Maintenance Treatment Group B
    Maintenance Treatment with Apatinib after First-line XELOX chemotherapy for Patients with Advanced Gastric Cancer

Primary Outcome Measure

PFS [ Time Frame: 36 months ]

Central Contacts

Related Studies